| __timestamp | BioCryst Pharmaceuticals, Inc. | Halozyme Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 122000 | 22732000 |
| Thursday, January 1, 2015 | 1896000 | 29245000 |
| Friday, January 1, 2016 | 2699000 | 33206000 |
| Sunday, January 1, 2017 | 1702000 | 31152000 |
| Monday, January 1, 2018 | 471000 | 10136000 |
| Tuesday, January 1, 2019 | 4101000 | 45546000 |
| Wednesday, January 1, 2020 | 1676000 | 43367000 |
| Friday, January 1, 2021 | 7264000 | 81413000 |
| Saturday, January 1, 2022 | 6594000 | 139304000 |
| Sunday, January 1, 2023 | 4661000 | 192361000 |
Data in motion
In the competitive world of biotechnology, understanding cost structures is crucial for investors and stakeholders. This analysis compares the cost of revenue for Halozyme Therapeutics, Inc. and BioCryst Pharmaceuticals, Inc. from 2014 to 2023. Over this period, Halozyme consistently outpaced BioCryst, with its cost of revenue peaking at nearly $193 million in 2023, a staggering 1,500% increase from 2014. In contrast, BioCryst's costs showed a more modest growth, reaching approximately $7.3 million in 2021, before slightly declining.
This disparity highlights Halozyme's aggressive expansion and scaling strategies, while BioCryst appears to maintain a more conservative approach. Investors should consider these trends when evaluating potential growth and profitability. The data underscores the importance of strategic financial management in the biotech sector, where innovation and cost efficiency are key to long-term success.
Cost of Revenue Comparison: AbbVie Inc. vs Halozyme Therapeutics, Inc.
Cost of Revenue: Key Insights for United Therapeutics Corporation and BioCryst Pharmaceuticals, Inc.
Cost of Revenue Trends: Neurocrine Biosciences, Inc. vs Halozyme Therapeutics, Inc.
Analyzing Cost of Revenue: Intra-Cellular Therapies, Inc. and Halozyme Therapeutics, Inc.
Cost Insights: Breaking Down Jazz Pharmaceuticals plc and Halozyme Therapeutics, Inc.'s Expenses
Cost of Revenue Comparison: Jazz Pharmaceuticals plc vs BioCryst Pharmaceuticals, Inc.
Halozyme Therapeutics, Inc. vs Lantheus Holdings, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue Comparison: Halozyme Therapeutics, Inc. vs Wave Life Sciences Ltd.
Cost Insights: Breaking Down Halozyme Therapeutics, Inc. and Viridian Therapeutics, Inc.'s Expenses
Cost Insights: Breaking Down Alkermes plc and BioCryst Pharmaceuticals, Inc.'s Expenses
Cost Insights: Breaking Down Geron Corporation and BioCryst Pharmaceuticals, Inc.'s Expenses
Cost of Revenue: Key Insights for Amphastar Pharmaceuticals, Inc. and BioCryst Pharmaceuticals, Inc.